NEW YORK – AstraZeneca and Daiichi Sankyo said on Tuesday that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorization to their antibody drug conjugate trastuzumab deruxtecan (Enhertu) as a monotherapy for previously-treated, metastatic, HER2-positive breast cancer patients.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.